Market closed
XOMA/$XOMA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About XOMA
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Ticker
$XOMA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
13
Website
XOMA Metrics
BasicAdvanced
$347M
Market cap
-
P/E ratio
-$3.05
EPS
0.90
Beta
-
Dividend rate
Price and volume
Market cap
$347M
Beta
0.9
52-week high
$33.31
52-week low
$14.77
Average daily volume
34K
Financial strength
Current ratio
7.524
Quick ratio
7.408
Long term debt to equity
128.15
Total debt to equity
140.248
Interest coverage (TTM)
-1.40%
Management effectiveness
Return on assets (TTM)
-5.54%
Return on equity (TTM)
-31.41%
Valuation
Price to revenue (TTM)
15.84
Price to book
4.09
Price to tangible book (TTM)
4.09
Price to free cash flow (TTM)
-16.877
Growth
Revenue change (TTM)
389.82%
Earnings per share change (TTM)
8.75%
3-year revenue growth (CAGR)
-10.16%
3-year earnings per share growth (CAGR)
233.67%
What the Analysts think about XOMA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for XOMA stock.
XOMA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
XOMA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
XOMA News
AllArticlesVideos
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
GlobeNewsWire·1 month ago
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
GlobeNewsWire·2 months ago
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for XOMA stock?
XOMA (XOMA) has a market cap of $347M as of December 12, 2024.
What is the P/E ratio for XOMA stock?
The price to earnings (P/E) ratio for XOMA (XOMA) stock is 0 as of December 12, 2024.
Does XOMA stock pay dividends?
No, XOMA (XOMA) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next XOMA dividend payment date?
XOMA (XOMA) stock does not pay dividends to its shareholders.
What is the beta indicator for XOMA?
XOMA (XOMA) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.